More delays for Regeneron
The company gets another odronextamab knockback, while a key fianlimab readout is postponed.
FDA red and green lights: July 2025
Approvals come for Regeneron and Dizal, but Roche and Replimune see knockbacks.
Scancell pivots back to a subgroup
The company claims a 69% response rate with iSCIB1+, but only in a “target population”.
FDA rejects Replimune’s oncolytic virus
There are questions about vuso-vec’s supporting and confirmatory trials.
Erasca enters its pan-RAS era
The company deprioritises its lead project, naporafenib, shifting to two Joyo-originated assets.
Mural hits a wall
The company scraps nemvaleukin after the latest failure, of Artistry-6.
Mural fails to paint a convincing picture for nemvaleukin
The Artistry-7 Keytruda combo trial fails, spurring discontinuation in ovarian cancer.
What future for Lag3 blockade?
Opdualag chalks up another failure, this time in the extension of an approved use.
